Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 6/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303667 | 0.98 | MAPT (0.41) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL17138740 | 0.95 | KDM4E (0.36) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL9410053 | 0.93 | MAPT (0.36) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL1810152 | 0.93 | MAPT (0.36) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL30776774 | 0.88 | KDM4E (0.35) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL13158345 | 0.88 | L3MBTL1 (0.40) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL17138565 | 0.88 | L3MBTL1 (0.40) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL13158339 | 0.88 | CCR2 (0.41) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL12116735 | 0.86 | CCR2 (0.43) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL12116414 | 0.86 | CCR2 (0.43) | MAPTALDH1A1KDM4ECCR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3939971-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939971-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2021-06-10 | — | — | US | disclosed |
| EP-3129366-B1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYNCHRONICITY PHARMA INC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3129366-B1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYNCHRONICITY PHARMA INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10759777-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Synchronicity Pharma, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2015157182-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-5003082-A | Reacting a lactam with hydrogen sulfide in the presence of an inorganic catalyst | PHILLIPS PETROLEUM COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| US-4990628-A | Reacting lactam with hydrogen sulfide in presence of group 8 metals or compounds on alumina; support; sulfiding | PHILLIPS PETROLEUM COMPANY (US) | 1991-02-05 | — | — | US | disclosed |
| US-4956476-A | Catalytic reaction of a lactam with hydrogen sulfide to produce a thiolactam, alumina is the catalyst | PHILLIPS PETROLEUM COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| US-4145352-A | SULFACTIVE CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885ALDH1A1 2882/4885KDM4E 1254/4885 |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885ALDH1A1 2882/4885KDM4E 1254/4885 |
| US-10759777-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | MAPT 1593/4885ALDH1A1 2882/4885KDM4E 1254/4885 |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885ALDH1A1 2882/4885KDM4E 1254/4885 |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | MAPT 1593/4885ALDH1A1 2882/4885KDM4E 1254/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885ALDH1A1 2882/4885KDM4E 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.